Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1986 Sep;54(3):431–437. doi: 10.1038/bjc.1986.194

Prostacyclin and thromboxane in benign and malignant breast tumours.

G M Laekeman, I B Vergote, G M Keersmaekers, J Heiremans, C F Haensch, G de Roy, F L Uyttenbroeck, A G Herman
PMCID: PMC2001625  PMID: 3530307

Abstract

6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-disease tissues (P less than 0.05). The 6-keto-PGF1 alpha/TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P less than 0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1 alpha/TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1 alpha/TXB2 ratios (P = 0.01) whereas the latter value was higher when infiltration was lower (P = 0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1 alpha/TXB2 ratio (P = 0.04). Cumulation of variables revealed lower prostanoid ratios in tumours greater than 2 cm without lymph node metastasis then tumours less than 2 cm with lymph node metastasis (P = 0.04). A first follow-up (14 months) showed a higher 6-keto-PGF1 alpha/TXB2 ratio in patients who developed metastasis (P = 0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer.

Full text

PDF
431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitokallio-Tallberg A., Kärkkäinen J., Pantzar P., Wahlström T., Ylikorkala O. Prostacyclin and thromboxane in breast cancer: relationship between steroid receptor status and medroxyprogesterone acetate. Br J Cancer. 1985 May;51(5):671–674. doi: 10.1038/bjc.1985.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett A., McDonald A. M., Simpson J. S., Stamford I. F. Breast cancer, prostaglandins, and bone metastases. Lancet. 1975 May 31;1(7918):1218–1220. doi: 10.1016/s0140-6736(75)92197-2. [DOI] [PubMed] [Google Scholar]
  3. Brune K., Glatt M., Kälin H., Peskar B. A. Pharmacological control of prostaglandin and thromboxane release from macrophages. Nature. 1978 Jul 20;274(5668):261–263. doi: 10.1038/274261a0. [DOI] [PubMed] [Google Scholar]
  4. Bunting S., Moncada S., Vane J. R. The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull. 1983 Jul;39(3):271–276. doi: 10.1093/oxfordjournals.bmb.a071832. [DOI] [PubMed] [Google Scholar]
  5. Elias E. G., Sepulveda F., Mink I. B. Increasing the efficiency of cancer chemotherapy with heparin: "clinical study". J Surg Oncol. 1973;5(2):189–193. doi: 10.1002/jso.2930050212. [DOI] [PubMed] [Google Scholar]
  6. Gasic G. J., Gasic T. B., Galanti N., Johnson T., Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 1973 May;11(3):704–718. doi: 10.1002/ijc.2910110322. [DOI] [PubMed] [Google Scholar]
  7. Granström E., Kindahl H. Radioimmunoassay of prostaglandins and thromboxanes. Adv Prostaglandin Thromboxane Res. 1978;5:119–210. [PubMed] [Google Scholar]
  8. Greaves M., Ibbotson K. J., Atkins D., Martin T. J. Prostaglandins as mediators of bone resorption in renal and breast tumours. Clin Sci (Lond) 1980 Mar;58(3):201–210. doi: 10.1042/cs0580201. [DOI] [PubMed] [Google Scholar]
  9. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Honn K. V., Cicone B., Skoff A. Prostacyclin: a potent antimetastatic agent. Science. 1981 Jun 12;212(4500):1270–1272. doi: 10.1126/science.7015512. [DOI] [PubMed] [Google Scholar]
  11. Humes J. L., Bonney R. J., Pelus L., Dahlgren M. E., Sadowski S. J., Kuehl F. A., Jr, Davies P. Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature. 1977 Sep 8;269(5624):149–151. doi: 10.1038/269149a0. [DOI] [PubMed] [Google Scholar]
  12. Karmali R. A., Welt S., Thaler H. T., Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer. 1983 Nov;48(5):689–696. doi: 10.1038/bjc.1983.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kibbey W. E., Bronn D. G., Minton J. P. Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma. Prostaglandins Med. 1979 Feb;2(2):133–139. doi: 10.1016/0161-4630(79)90048-x. [DOI] [PubMed] [Google Scholar]
  14. Lione A., Bosmann H. B. The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice. Cell Biol Int Rep. 1978 Jan;2(1):81–86. doi: 10.1016/0309-1651(78)90087-5. [DOI] [PubMed] [Google Scholar]
  15. Malachi T., Chaimoff C., Feller N., Halbrecht I. Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. J Cancer Res Clin Oncol. 1981;102(1):71–79. doi: 10.1007/BF00410536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  17. Peskar B. M., Weiler H., Schmidberger P., Peskar B. A. On the occurrence of prostacyclin metabolites in plasma and vascular tissue as determined radioimmunologically. FEBS Lett. 1980 Nov 17;121(1):25–28. doi: 10.1016/0014-5793(80)81258-0. [DOI] [PubMed] [Google Scholar]
  18. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
  19. Sloane B. F., Dunn J. R., Honn K. V. Lysosomal cathepsin B: correlation with metastatic potential. Science. 1981 Jun 5;212(4499):1151–1153. doi: 10.1126/science.7233209. [DOI] [PubMed] [Google Scholar]
  20. Vergote I. B., Laekeman G. M., Keersmaekers G. H., Uyttenbroeck F. L., Vanderheyden J. S., Albertyn G. P., Haensch C. F., De Roy G. J., Herman A. G. Prostaglandin F2 alpha in benign and malignant breast tumours. Br J Cancer. 1985 Jun;51(6):827–836. doi: 10.1038/bjc.1985.128. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES